Progyny (NASDAQ:PGNY) Issues FY 2022 Earnings Guidance

Progyny (NASDAQ:PGNYGet Rating) updated its FY 2022 earnings guidance on Thursday. The company provided EPS guidance of $0.14-$0.19 for the period, compared to the consensus EPS estimate of $0.09. The company issued revenue guidance of $750.00 million-$775.00 million, compared to the consensus revenue estimate of $756.81 million. Progyny also updated its FY22 guidance to $0.14-$0.19 EPS.

Progyny Stock Performance

NASDAQ:PGNY traded up $11.38 on Friday, hitting $41.15. 3,469,925 shares of the stock were exchanged, compared to its average volume of 684,594. The stock has a market capitalization of $3.78 billion, a price-to-earnings ratio of 89.46, a P/E/G ratio of 21.71 and a beta of 1.85. Progyny has a 52 week low of $25.67 and a 52 week high of $68.32. The company’s 50-day moving average price is $30.23 and its 200 day moving average price is $37.32.

Progyny (NASDAQ:PGNYGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.04. The firm had revenue of $195.00 million during the quarter, compared to analysts’ expectations of $190.51 million. Progyny had a return on equity of 18.11% and a net margin of 7.39%. The company’s quarterly revenue was up 51.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.19 EPS. As a group, equities research analysts predict that Progyny will post 0.17 earnings per share for the current year.

Insider Activity

In other news, Chairman David J. Schlanger sold 1,452 shares of the company’s stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $31.21, for a total value of $45,316.92. Following the completion of the sale, the chairman now directly owns 82,548 shares of the company’s stock, valued at approximately $2,576,323.08. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Chairman David J. Schlanger sold 1,452 shares of the company’s stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $31.21, for a total value of $45,316.92. Following the completion of the sale, the chairman now directly owns 82,548 shares of the company’s stock, valued at approximately $2,576,323.08. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Norman Payson sold 6,618 shares of the company’s stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $32.27, for a total value of $213,562.86. Following the completion of the sale, the director now directly owns 411,412 shares of the company’s stock, valued at $13,276,265.24. The disclosure for this sale can be found here. Insiders sold a total of 41,240 shares of company stock valued at $1,291,601 in the last ninety days. 14.00% of the stock is owned by insiders.

Institutional Trading of Progyny

Large investors have recently bought and sold shares of the business. Lazard Asset Management LLC bought a new stake in Progyny during the 1st quarter worth approximately $62,000. Parkside Financial Bank & Trust bought a new stake in Progyny during the 1st quarter worth approximately $70,000. Captrust Financial Advisors increased its stake in Progyny by 25.0% during the 1st quarter. Captrust Financial Advisors now owns 2,091 shares of the company’s stock worth $107,000 after purchasing an additional 418 shares in the last quarter. Mackenzie Financial Corp bought a new stake in Progyny during the 1st quarter worth approximately $216,000. Finally, Bank of Montreal Can increased its stake in Progyny by 25.2% during the 1st quarter. Bank of Montreal Can now owns 7,278 shares of the company’s stock worth $381,000 after purchasing an additional 1,465 shares in the last quarter. 82.51% of the stock is owned by institutional investors.

Progyny Company Profile

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Articles

Earnings History and Estimates for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.